Radiofrequency and Pelvic Floor Exercise for Primary Dysmenorrhea
Effectiveness of Radiofrequency and Physical Exercise on Symptoms Associated With Primary Dysmenorrhea: a Randomised Clinical Trial
The goal of this clinical trial is to learn whether radiofrequency (a heat-producing electrotherapy applied through an intravaginal electrode and over the abdomen), a supervised pelvic floor and core exercise programme, or both together reduce menstrual pain in women aged 18 to 35 years with primary dysmenorrhea. The main question it aims to answer is: do the three treatments differ in menstrual pain intensity (0-10 visual analogue scale)? Researchers will also compare pain quality, use of painkillers, quality of life, sexual function, premenstrual symptoms, pelvic floor muscle function and satisfaction with treatment, up to 1 year after treatment.
One hundred and twenty women will be randomly assigned to one of three groups:
- Radiofrequency: eight weekly sessions of about 30 minutes.
- Exercise: 16 supervised group sessions of 45 minutes (twice a week for 8 weeks).
- Combined: both treatments. Participants will complete questionnaires, a pain-medication diary and a pelvic floor examination before treatment and 1 week, 6 months and 1 year after treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background. Primary dysmenorrhea affects more than 60% of women under 25 years and is a leading cause of school and work absenteeism. First-line treatment with non-steroidal anti-inflammatory drugs or oral contraceptives fails in 20-25% of women and causes side effects. Heat therapy reduces menstrual pain, and capacitive-resistive radiofrequency (RF) has reduced pain in chronic pelvic pain. Exercise is the reference conservative treatment for primary dysmenorrhea, but no trial has compared intravaginal RF, exercise and their combination.
Design. Randomised clinical trial with three parallel arms and 1:1:1 allocation, conducted at a gynaecology clinic in Elche, Spain (NG Clínicas - Juana Lafaja Mazuecos) in collaboration with Universidad CEU Cardenal Herrera. At baseline, a gynaecologist performs a transvaginal ultrasound in the proliferative phase to exclude secondary dysmenorrhea and to record uterine position. An investigator blinded to the baseline assessments generates the allocation sequence with SAS 9.4; allocation is kept in sealed, opaque, numbered envelopes. The statistician is blinded to allocation. Participants and therapists cannot be blinded.
Interventions. RF (Capenergy C500 Urogyne, capacitive transfer): eight weekly sessions. Each session starts with an athermic application for 10 minutes, with the active plate on the abdomen and the passive plate on the lumbar region. This is followed by an intravaginal application with a covered, lubricated MJS electrode for 20 minutes at a high thermal sensation (up to 43-44 °C), sweeping from 3 to 9 o'clock towards the vaginal fornix according to uterine position. Exercise: 16 group sessions (up to 8 participants) of 45 minutes, twice a week for 8 weeks, led by a physiotherapist. The programme combines pelvic floor and core activation, strength, aerobic and relaxation exercises, with progression after week 4. The combined group receives both.
Outcomes. The primary outcome is menstrual pain intensity on a visual analogue scale. Secondary outcomes are the McGill Pain Questionnaire, analgesic consumption (diary), EQ-5D, Female Sexual Function Index, Premenstrual Symptoms Screening Tool, pelvic floor muscle function (PERFECT scheme, modified Oxford scale and Phenix manometry) and treatment satisfaction. Assessments take place at baseline, 1 week, 6 months and 1 year after the end of treatment.
Sample size and analysis. A total of 120 women (40 per arm), assuming 25% attrition, α = 0.05 and 80% power. Intention-to-treat analysis using repeated-measures ANOVA (group × time) in SPSS 29.
Ethics. Approved by the Biomedical Research Ethics Committee of Universidad CEU Cardenal Herrera (CEEI25/670, 7 April 2025).
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: SERGIO MONTERO NAVARRO, PhD
- Numéro de téléphone: 67604 +34 965 42 64 86
- E-mail: sergio.montero@uchceu.es
Sauvegarde des contacts de l'étude
- Nom: Cristina Orts-Ruiz, PhD
- E-mail: cristina.orts@uchceu.es
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women aged 18 to 35 years with a regular menstrual cycle (24 to 35 days).
- Normal genital ultrasound without clinical signs of organic disease.
- Primary dysmenorrhea present in all menstrual cycles since menarche.
- Menstrual pain of 5 or more on a 0-10 visual analogue scale.
- Body mass index between 20 and 30 kg/m².
Exclusion Criteria:
- Gynaecological findings consistent with secondary dysmenorrhea (pelvic inflammatory disease, uterine fibroids, polyps, endometriosis, adenomyosis, cervicitis).
- Pregnancy, or breastfeeding at the time of the study.
- Use of an intrauterine contraceptive device.
- Physiotherapist-supervised pelvic floor muscle training, or radiofrequency to the pelvic region, in the previous 12 months.
- Inability to understand study information (cognitive impairment).
- Peripheral or central neurological disorders.
- Previous pelvic surgery.
- Skin disease or wounds in the treatment area.
- Active urinary tract or vaginal infection.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Radiofrequency
Eight weekly sessions of capacitive radiofrequency: athermic abdominal-lumbar application (10 min) followed by intravaginal application (20 min). |
Capenergy C500 Urogyne (capacitive transfer; 0.8, 1 and 1.2 MHz; temperature sensor). (1) Athermic application for 10 min with the active plate on the abdomen and the passive plate on the lumbar region. (2) Intravaginal application with a covered, lubricated MJS electrode for 20 min at a high thermal sensation (up to 43-44 °C), sweeping from 3 to 9 o'clock; the electrode orientation and passive plate position (lumbosacral or abdominal) depend on uterine position on ultrasound. Eight sessions at 7-day intervals. Temperature reached and delivered energy (kJ) are recorded each session. |
|
Comparateur actif: Therapeutic exercise
Supervised pelvic floor and core exercise programme in groups of up to 8: 45-minute sessions twice a week for 8 weeks (16 sessions). |
First session individual, with anatomy, breathing and technique checked by digital testing. The following sessions are group-based: pelvic floor and transversus activation, glute bridge variations, resisted expiration and apnoea exercises, balance and motor control, squats and lunges, planks, and kettlebell work from week 4. Each session ends with active stretching and relaxation. Two different sessions per week for 8 weeks, 45 min each. |
|
Expérimental: Radiofrequency + therapeutic exercise
Both interventions over the same 8-week period. |
Capenergy C500 Urogyne (capacitive transfer; 0.8, 1 and 1.2 MHz; temperature sensor). (1) Athermic application for 10 min with the active plate on the abdomen and the passive plate on the lumbar region. (2) Intravaginal application with a covered, lubricated MJS electrode for 20 min at a high thermal sensation (up to 43-44 °C), sweeping from 3 to 9 o'clock; the electrode orientation and passive plate position (lumbosacral or abdominal) depend on uterine position on ultrasound. Eight sessions at 7-day intervals. Temperature reached and delivered energy (kJ) are recorded each session. First session individual, with anatomy, breathing and technique checked by digital testing. The following sessions are group-based: pelvic floor and transversus activation, glute bridge variations, resisted expiration and apnoea exercises, balance and motor control, squats and lunges, planks, and kettlebell work from week 4. Each session ends with active stretching and relaxation. Two different sessions per week for 8 weeks, 45 min each. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menstrual pain intensity (Visual Analogue Scale)
Délai: Baseline and 1 week after the end of the 8-week intervention
|
Menstrual pain on a 0-10 cm visual analogue scale (0 = no pain, 10 = worst pain). Higher scores indicate worse pain |
Baseline and 1 week after the end of the 8-week intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menstrual pain intensity during follow-up (VAS)
Délai: 6 months and 1 year after the end of the intervention
|
0-10 cm VAS as for the primary outcome. |
6 months and 1 year after the end of the intervention
|
|
Pain quality (McGill Pain Questionnaire)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
Pain descriptors chosen from 20 subclasses, each with a specific score. Higher scores indicate greater pain. |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Analgesic consumption
Délai: Each menstrual cycle during the 8-week intervention
|
Number of analgesic doses taken for menstrual pain per cycle, recorded in a diary (date, time, drug and amount). |
Each menstrual cycle during the 8-week intervention
|
|
Health-related quality of life (EQ-5D)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
EuroQol-5D, five dimensions scored at 3 levels, plus a 0-100 visual analogue scale of health status. Higher VAS scores indicate better health. |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Sexual function (FSFI)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
Female Sexual Function Index, total score (range 2-36) over the previous 4 weeks. Scores of 26.55 or lower indicate sexual dysfunction; higher scores indicate better function. |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Premenstrual symptoms (PSST)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
Premenstrual Symptoms Screening Tool: 14 symptom items (total 0-42; higher scores indicate more severe symptoms) and 5 items on functional impact. |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Pelvic floor muscle function (PERFECT scheme and modified Oxford scale)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
Digital vaginal assessment: power (modified Oxford 0-5), endurance (s), repetitions and fast contractions (number per 10 s). |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Intravaginal pressure (manometry)
Délai: Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
Phenix Liberty manometer with an air-filled probe: resting tone and mean of three maximal contractions held for 10 sec. |
Baseline, and 1 week, 6 months and 1 year after the end of the 8-week intervention.
|
|
Treatment satisfaction
Délai: 1 week after the end of the intervention
|
Five-point Likert scale (1 = very dissatisfied, 5 = very satisfied). |
1 week after the end of the intervention
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse events
Délai: From the first session to 1 year after the intervention
|
Number of participants with adverse events (e.g. burns, marked irritation or persistent pain), by group. |
From the first session to 1 year after the intervention
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Cristina Orts-Ruiz, PhD, CEU Cardenal Herrera University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CEEI25/670
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .